Calgary, Alberta, July 31, 2024 – Resverlogix Corp. (“Resverlogix”, or the "Corporation") (TSX:RVX) today held its Annual & Special Meeting of Shareholders (the “Meeting”) in Calgary, Alberta.
During business proceedings at the Meeting, shareholders elected four (4) Board members until the next annual meeting. The voting results of shares represented at the Meeting for individual directors were as follows:
|
| Votes For | Votes Withheld | Percent For | Percent Withheld |
| Donald J. McCaffrey | 131,554,931 | 6,759,498 | 95.11% | 4.89% |
| Kelly McNeill | 132,370,485 | 5,943,944 | 95.70% | 4.30% |
| Siu Lun (Dicky) To | 132,663,593 | 5,650,836 | 95.91% | 4.09% |
| Kenneth Zuerblis | 132,354,299 | 5,960,130 | 95.69% | 4.31% |
Resverlogix shareholders approved all resolutions outlined in the Notice of Meeting and Management Information Circular dated June 14, 2024 (the “Information Circular”). The Information Circular is available on SEDAR at www.sedar.com, and on the Resverlogix website at www.resverlogix.com.
A webcast archive of the executive presentation portion of the Meeting will be available HERE.
Resverlogix also announced that it has closed the previously-announced two year extension of its US$6.0 million secured debenture with Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
About Resverlogix
Founded in 2001, Resverlogix is a Calgary based late-stage biotechnology company, and a world leader in epigenetics, with the goal of developing first-in-class therapies for the benefit of patients with chronic disease.
Resverlogix is developing a new class of epigenetic therapies designed to regulate the expression of disease-causing genes. We aim to improve patients’ lives by restoring biological functions – altered by serious illnesses such as cardiovascular disease – back to a healthier state.
The Company’s clinical program is focused on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post COVID-19 conditions.
Resverlogix has partnered with EVERSANA™, the pioneer of next generation commercial services to the global life sciences industry, to support the rapid commercialization of apabetalone for cardiovascular disease, post COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.
Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX).
Follow us on:
- Twitter: @Resverlogix_RVX
- LinkedIn: https://www.linkedin.com/company/resverlogix-corp-/
Forward Looking Statements:
This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts”, and other similar expressions. In particular, this news release includes forward looking information related to the potential role of apabetalone in the treatment of patients with cardiovascular disease, post COVID-19 conditions, pulmonary arterial hypertension, associated comorbidities, and other chronic diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For further information please contact:
Investor Relations
Email: ir@resverlogix.com
Phone: 403-254-9252
www.resverlogix.com